Lilly’s Mounjaro turns into world’s best-selling drug

THE WHAT? Eli Lilly’s diabetes remedy Mounjaro has overtaken Merck’s most cancers remedy Keytruda to grow to be the world’s top-selling pharmaceutical product.

THE DETAILS Mounjaro generated US$8.7 billion in first-quarter 2026 gross sales, surpassing Keytruda’s US$7.9 billion income throughout the identical interval. Keytruda had held the place because the world’s best-selling drug since early 2023. Lilly’s efficiency turns into even stronger when mixed with weight problems drug Zepbound, which makes use of the identical energetic ingredient, tirzepatide. Collectively, the 2 merchandise generated US$36.5 billion in 2025 gross sales, exceeding Keytruda’s annual income of US$31.6 billion. Analysts stated demand for weight problems and diabetes remedies continues to speed up globally because of the effectiveness and security profile of GLP-1 medicines. In the meantime, Merck is getting ready for Keytruda’s patent expiry in 2028, which is anticipated to intensify strain on the corporate’s oncology enterprise.

THE WHY? The shift highlights the fast rise of weight problems and diabetes remedies as one of many pharmaceutical business’s most commercially vital classes, reshaping the worldwide healthcare and wellness market.

Supply: Bloomberg